Date/Time
Date(s) - 6 Oct 2025 until 8 Oct 2025
7:00 AM - 7:00 PM
Location
Arizona Biltmore Resort
Join senior leaders and key decision makers in cell and gene therapy, gene editing and tissue engineering for the sector’s premier conference.
Dates & Location
October 6-8, 2025
Arizona Biltmore
Phoenix, AZ
Learn More & Register
The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 110+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 2,000 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 5,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.
The conference will be delivered in a hybrid format to allow for an in-person experience as well as a virtual participation option. The in-person conference will take place October 6-8 in Phoenix, AZ. Virtual registrants will have access to all content via livestream during program dates. Additionally, all content will be available on-demand within 24 hours of the live program time. Finally, the meeting will deploy its premier partnering system, partneringONE, allowing registrants to plan 1×1 meetings with the full attendee list beginning six weeks prior to the event. The in-person partnering meetings will take place October 6-8 and the virtual partnering meetings will take place October 9-10 via Zoom.
This year’s meeting will feature sessions and workshops covering a mix of commercialization topics related to the cell and gene therapy sector including the latest updates on market access and reimbursement schemes, international regulation harmonization, manufacturing and CMC challenges, investment opportunities for the sector, among others. Additionally, we will feature over 100 presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering and broader regenerative medicine technologies.